• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Mary-Ellen Taplin, MD


  • Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME.
    A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer.
    Clin Genitourin Cancer. 2015 Apr;13(2):113-23.
  • Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin ME, Taub JM, Herman B, Higano CS, Doot RK, Hartfeil D, Febbo PG, Mankoff DA.
    Castration-Resistant Prostate Cancer Bone Metastasis Response Measured by 18F-Fluoride PET After Treatment with Dasatinib and Correlation with Progression-Free Survival: Results from American College of Radiology Imaging Network 6687.
    J Nucl Med. 2015 Mar;56(3):354-60.
  • Higano CS, Beer TM, Taplin ME, Efstathiou E, Hirmand M, Forer D, Scher HI.
    Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.
    Eur Urol. 2015 Feb 16.
  • Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, .
    Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
    Lancet Oncol. 2015 Feb;16(2):152-60.
  • Zukotynski KA, Kim CK, Gerbaudo VH, Hainer J, Taplin ME, Kantoff P, den Abbeele AD, Seltzer S, Sweeney CJ.
    (18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer.
    Am J Nucl Med Mol Imaging. 2015;5(1):72-82.
  • McKay RR, Mamlouk K, Montgomery B, Taplin ME.
    Treatment With Galeterone in an Elderly Man With Castration-Resistant Prostate Cancer: A Case Report.
    Clin Genitourin Cancer. 2014 Dec 31.
  • Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ.
    Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
    Clin Genitourin Cancer. 2014 Dec 9.
  • Tamae D, Mostaghel E, Montgomery B, Nelson PS, Balk SP, Kantoff PW, Taplin M, Penning TM.
    The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.
    Chem. Biol. Interact. 2014 Dec 13.
  • Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis JM, Zhang CZ, Shalek AK, Satija R, Trombetta JJ, Lu D, Tallapragada N, Tahirova N, Kim S, Blumenstiel B, Sougnez C, Lowe A, Wong B, Auclair D, Van Allen EM, Nakabayashi M, Lis RT, Lee GS, Li T, Chabot MS, Ly A, Taplin ME, Clancy TE, Loda M, Regev A, Meyerson M, Hahn WC, Kantoff PW, Golub TR, Getz G, Boehm JS, Love JC.
    Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer.
    Nat Biotechnol. 2014 May(5):479-84.
  • Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, Shapiro GI, Sabatini DM, Lander ES, Gabriel SB, Kantoff PW, Garraway LA, Rosenberg JE.
    Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.
    Cancer Discovery. 2014 May(5):546-53.
  • Fennessy FM, McKay RR, Beard CJ, Taplin ME, Tempany CM.
    Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls.
    Transl Oncol. 2014 Feb;7(1):120-9.
  • Yao X, Choudhury AD, Yamanaka YJ, Adalsteinsson VA, Gierahn TM, Williamson CA, Lamb CR, Taplin ME, Nakabayashi M, Chabot MS, Li T, Lee GS, Boehm JS, Kantoff PW, Hahn WC, Wittrup KD, Love JC.
    Functional analysis of single cells identifies a rare subset of circulating tumor cells with malignant traits.
    Integr Biol (Camb). 2014 Apr 1;6(4):388-98.
  • Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F.
    Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302).
    Eur Urol. 2014 Mar 6.
  • Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B.
    Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
    J Clin Oncol. 2014 Jan 20;32(3):229-37.
  • McKay RR, Taplin ME, Choueiri TK.
    Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer.
    Hematol Oncol Clin North Am. 2013 Dec;27(6):1261-83, ix.
  • Harshman LC, Taplin ME.
    Abiraterone acetate: targeting persistent androgen dependence in castration-resistant prostate cancer.
    Adv Ther. 2013 Aug;30(8):727-47.
  • Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh W, Morganstern DE, Kantoff PW, Taplin ME.
    Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
    Urology. 2013 Mar;81(3):611-6.
  • Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, .
    Abiraterone in metastatic prostate cancer without previous chemotherapy.
    N Engl J Med. 2013 Jan 10;368(2):138-48.
  • Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME.
    Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.
    BJU Int. 2012 Aug 29.
  • Vinjamoori AH, Jagannathan JP, Shinagare AB, Taplin ME, Oh WK, Van den Abbeele AD, Ramaiya NH.
    Atypical metastases from prostate cancer: 10-year experience at a single institution.
    AJR Am J Roentgenol. 2012 Aug;199(2):367-72.
  • Shinagare AB, Fennessy FM, Ramaiya NH, Jagannathan JP, Taplin ME, Van den Abbeele AD.
    Urothelial cancers of the upper urinary tract: metastatic pattern and its correlation with tumor histopathology and location.
    J Comput Assist Tomogr.;35(2):217-22.
  • Wu Y, Rosenberg JE, Taplin ME.
    Novel agents and new therapeutics in castration-resistant prostate cancer.
    Curr Opin Oncol. 2011 Feb 9.
  • Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD.
    Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor.
    AJR Am J Roentgenol. 2011 Jan;196(1):117-22.
  • Nakabayashi M, Oh WK, Jacobus S, Regan MM, Taplin ME, Kantoff PW, Rosenberg JE.
    Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.
    BJU Int. 2010 May;105(10):1392-6.
  • Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL, .
    Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
    Lancet. 2010 Apr 24;375(9724):1437-46.
  • Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI.
    Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2010 Mar 20;28(9):1496-501.
  • Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP.
    Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer.
    Clin Cancer Res. 2009 Nov 15;15(22):7099-105.
  • Sartor O, Nakabayashi M, Taplin ME, Ross RW, Kantoff PW, Balk SP, Oh WK.
    Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.
    Clin Genitourin Cancer. 2009 Oct;7(3):E90-2.
  • Choueiri TK,Xie W,D'Amico AV,Ross RW,Hu JC,Pomerantz M,Regan MM,Taplin ME,Kantoff PW,Sartor O,Oh WK.
    Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
    Cancer. 2009 Mar 1;115(5):981-7.
  • Taplin ME.
    Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Expert Rev Anticancer Ther. 2008 Sep;8(9):1495-508. Review.
  • Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP.
    A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.
    BJU Int. 2008 May;101(9):1084-9.
  • Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK.
    Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Cancer. 2008 Mar 15;112(6):1247-53.
  • Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M.
    Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
    J Clin Oncol. 2008 Feb 20;26(6):842-7.
  • Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK.
    Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.
    BJU Int. 2008 Feb;101(3):308-12.
  • Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK.
    A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
    Cancer. 2008 Feb 1;112(3):521-6.
  • Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK.
    Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.
    J Urol. 2007 Jun;177(6):2146-50.
  • Taplin ME.
    Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
    Nat Clin Pract Oncol. 2007 Apr;4(4):236-44. Review.
  • Taplin ME, Xie W, Bubley GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM.
    Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.
    J Clin Oncol. 2006 Dec 1;24(34):5408-13.
  • Taplin ME.
    Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective.
    Rev Urol. 2003;5 Suppl 2:S3-S13.
  • , Berry DL, Moinpour CM, Jiang CS, Ankerst DP, Petrylak DP, Vinson LV, Lara PN, Jones S, Taplin ME, Burch PA, Hussain MH, Crawford ED.
    Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
    J Clin Oncol. 2006 Jun 20;24(18):2828-35.
  • Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED.
    Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
    J Natl Cancer Inst. 2006 Apr 19;98(8):516-21.
  • Ross RW, Halabi S, Ou SS, Rajeshkumar BR, Woda BA, Vogelzang NJ, Small EJ, Taplin ME, Kantoff PW,.
    Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study.
    Clin Cancer Res. 2005 Nov 15;11(22):8109-13.
  • Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, Oh WK.
    Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
    BJU Int. 2005 Oct;96(6):783-6.
  • Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW.
    Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.
    Urology. 2005 Aug;66(2):386-91.
  • Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED.
    Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
    N Engl J Med. 2004 Oct 7;351(15):1513-20.
  • Mobley JA, Lam YW, Lau KM, Pais VM, L'Esperance JO, Steadman B, Fuster LM, Blute RD, Taplin ME, Ho SM.
    Monitoring the serological proteome: the latest modality in prostate cancer detection.
    J Urol. 2004 Jul;172(1):331-7.
  • Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, Middleton R, Porterfield H, Sharp SA, Smith TJ, Taplin ME, Vogelzang NJ, Wade JL, Bennett CL, Scher HI.
    American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.
    J Clin Oncol. 2004 Jul 15;22(14):2927-41.
  • Taplin ME, Balk SP.
    Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.
    J Cell Biochem. 2004 Feb 15;91(3):483-90.
  • Chun NS, Savani B, Seder RH, Taplin ME.
    Acute renal failure after intravenous anti-D immune globulin in an adult with immune thrombocytopenic purpura.
    Am J Hematol. 2003 Dec;74(4):276-9.
  • Taplin ME, Kantoff PW.
    The ingredients for prostate cancer nomograms: the addition of biomarkers sets the table for future recipes.
    J Clin Oncol. 2003 Oct 1;21(19):3552-3.
  • Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ,.
    Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.
    J Clin Oncol. 2003 Jul 15;21(14):2673-8.
  • Taplin ME, Bubley GJ, Rajeshkumar B, Shuster T, Ko YJ, Morganstern DE.
    Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.
    Semin Oncol. 2001 Aug;28(4 Suppl 15):32-9.
  • Taplin ME, Ho SM.
    Clinical review 134: The endocrinology of prostate cancer.
    J Clin Endocrinol Metab. 2001 Aug;86(8):3467-77.
  • Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H, Ho SM.
    Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma.
    Am J Pathol. 2001 Jul;159(1):79-92.
  • Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ.
    Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.
    J Clin Oncol. 2001 May 1;19(9):2509-16.
  • Savarese D, Taplin ME, Halabi S, Hars V, Kreis W, Vogelzang N.
    A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
    Semin Oncol. 1999 Oct;26(5 Suppl 17):39-44.
  • Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP.
    Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
    Cancer Res. 1999 Jun 1;59(11):2511-5.
  • Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP.
    Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.
    Clin Cancer Res. 1997 Aug;3(8):1383-8.
  • Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ.
    High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.
    J Urol. 1998 Jan;159(1):149-53.
  • Taplin ME, Frantz ME, Canning C, Ritz J, Blumberg RS, Balk SP.
    Evidence against T-cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expression.
    Immunology. 1996 Mar;87(3):402-7.
  • Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP.
    Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.
    N Engl J Med. 1995 May 25;332(21):1393-8.